New hope for tough AML: drug cocktail targets resistant leukemia
NCT ID NCT04774393
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This study is testing a combination of oral medications for acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs include decitabine/cedazuridine, venetoclax, and either ivosidenib or enasidenib. The goal is to see if this combination is safe and effective in controlling the disease. About 84 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine, cedazuridine, venetoclax, ivosidenib, or enasidenib
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat AML, potentially improving remission rates.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug combination may cause side effects or not work as expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.